The subject of the contract consists in the supply of various medicinal products (ATC subgroups L01 and L04), intravenous injectable forms. The description of the supplies requested shall be included in the procurement documents. The establishments that will be parties to the contracts to be concluded at the end of the procedure are: - the Centre Hospitalier Émile Mayrisch (CHEM), - the Centre Hospitalier de Luxembourg (CHL), - the Centre Hospitalier du Nord (CHdN), and - the Robert Schuman Hospitals (HRS).

Brentuximab vedotin, intravenous injection form, 50 mg.

Carfilzomib, intravenous injectable form, 60 mg.

Elotuzumab, intravenous injectable forms, 300 mg and 400 mg.

Natalizumab, intravenous injection form, 20 mg / ml.

Obinutuzumab, intravenous injectable form, 1000 mg, 1000 mg/40ml.

Pertuzumab intravenous form for injection, 420 mg, 420 mg/14 ml.

Vedolizumab, intravenous injection form, 300 mg, 20 ml.